Zealand Pharma A/S (22Z F) stock market data APIs
€49.5559
0.59(1.2%)
as of July 8, 2025
Try our APIs with
free plan!
Zealand Pharma A/S Financial Data Overview
Price chart is built with
Anychart
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S was incorporated in 1997 and is based in Søborg, Denmark.
Prev. Close
49.5559
Open
50.1458
High
50.1458
Low
49.5559
52 wk Range
46.51-129
Market Cap
3 546 M
Shares Outstanding
70 986 K
Revenue
55 694 K
Beta
0.562
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Zealand Pharma A/S data using free add-ons & libraries
Get Zealand Pharma A/S Fundamental Data
Zealand Pharma A/S Fundamental data includes:
- Net Revenue: 55 694 K
- EBITDA: -1 410 347 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Zealand Pharma A/S News
New
Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns.
Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with Lilly and Novo. Continue Reading View Comments
Total number of shares and voting rights in Zealand Pharma as of June 30, 2025
Zealand Pharma Company announcement – No. 16 / 2025 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ("the ...
Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
Zealand Pharma Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight re...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Zealand Pharma Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharm...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
